Stay updated on Safety & Efficacy of INCAGN01949 With Immune Therapies Clinical Trial
Sign up to get notified when there's something new on the Safety & Efficacy of INCAGN01949 With Immune Therapies Clinical Trial page.

Latest updates to the Safety & Efficacy of INCAGN01949 With Immune Therapies Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedRevision: v3.3.2 replaces v3.2.0; no visible changes to the study details or documentation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check28 days agoChange DetectedRemoved the government funding lapse notice from the page footer, removing guidance about potential data delays and operating status. This change does not affect the core study information or user actions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check49 days agoChange DetectedThe screenshots show the same study details page with no substantive content changes, only minor styling and layout tweaks. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check71 days agoChange DetectedCore content updated with a funding/operations notice and a version bump to v3.2.0; several cancer-type entries were removed.SummaryDifference2%

- Check78 days agoChange Detected- Updated terminology to a standardized form: 'Squamous cell carcinoma of the head and neck' replaces 'Head and neck squamous cell carcinoma'. - Revision/version updated from v3.0.2 to v3.1.0.SummaryDifference0.4%

- Check92 days agoChange DetectedUpdated the page revision from v3.0.1 to v3.0.2. The 'Back to Top' element was removed.SummaryDifference0.1%

Stay in the know with updates to Safety & Efficacy of INCAGN01949 With Immune Therapies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety & Efficacy of INCAGN01949 With Immune Therapies Clinical Trial page.